{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:26:33Z","timestamp":1792146393251,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T00:00:00Z","timestamp":1546387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T00:00:00Z","timestamp":1546387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Nematodes causing lymphatic filariasis and onchocerciasis rely on their bacterial endosymbiont,\n                    <jats:italic>Wolbachia<\/jats:italic>\n                    , for survival and fecundity, making\n                    <jats:italic>Wolbachia<\/jats:italic>\n                    a promising therapeutic target. Here we perform a high-throughput screen of AstraZeneca\u2019s 1.3 million in-house compound library and identify 5 novel chemotypes with faster in vitro kill rates (&lt;2 days) than existing anti-\n                    <jats:italic>Wolbachia<\/jats:italic>\n                    drugs that cure onchocerciasis and lymphatic filariasis. This industrial scale anthelmintic neglected tropical disease (NTD) screening campaign is the result of a partnership between the Anti-\n                    <jats:italic>Wolbachia<\/jats:italic>\n                    consortium (A\u2219WOL) and AstraZeneca. The campaign was informed throughout by rational prioritisation and triage of compounds using cheminformatics to balance chemical diversity and drug like properties reducing the chance of attrition from the outset. Ongoing development of these multiple chemotypes, all with superior time-kill kinetics than registered antibiotics with anti-\n                    <jats:italic>Wolbachia<\/jats:italic>\n                    activity, has the potential to improve upon the current therapeutic options and deliver improved, safer and more selective macrofilaricidal drugs.\n                  <\/jats:p>","DOI":"10.1038\/s41467-018-07826-2","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T13:01:03Z","timestamp":1545915663000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Industrial scale high-throughput screening delivers multiple fast acting macrofilaricides"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3945-0530","authenticated-orcid":false,"given":"Rachel H.","family":"Clare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bardelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. David","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"B\u00f6rjesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Myhill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Cassidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Plant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Plant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren A. N.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Steven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6361-1536","authenticated-orcid":false,"given":"Paul","family":"McGillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4447-3438","authenticated-orcid":false,"given":"Sitthivut","family":"Charoensutthivarakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn","family":"Bibby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma L.","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barton E.","family":"Slatko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Cantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2185-5476","authenticated-orcid":false,"given":"Joseph","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7919-2866","authenticated-orcid":false,"given":"Louise","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wigglesworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1928-0738","authenticated-orcid":false,"given":"Neil G.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,2]]},"reference":[{"key":"7826_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1017\/S0031182013001108","volume":"141","author":"MJ Taylor","year":"2014","unstructured":"Taylor, M. J., Hoerauf, A., Townson, S., Slatko, B. E. & Ward, S. A. Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis. Parasitology 141, 119\u2013127 (2014).","journal-title":"Parasitology"},{"key":"7826_CR2","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1039\/c4md00011k","volume":"5","author":"JN Burrows","year":"2014","unstructured":"Burrows, J. N. et al. The role of modern drug discovery in the fight against neglected and tropical diseases. MedChemComm 5, 688 (2014).","journal-title":"MedChemComm"},{"key":"7826_CR3","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMra064142","volume":"357","author":"PJ Hotez","year":"2007","unstructured":"Hotez, P. J. et al. Control of neglected tropical diseases. N. Engl. J. Med. 357, 1018\u20131027 (2007).","journal-title":"N. Engl. J. Med."},{"key":"7826_CR4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S0140-6736(16)30171-4","volume":"389","author":"DH Molyneux","year":"2017","unstructured":"Molyneux, D. H., Savioli, L. & Engels, D. Neglected tropical diseases: progress towards addressing the chronic pandemic. Lancet 389, 312\u2013325 (2017).","journal-title":"Lancet"},{"key":"7826_CR5","first-page":"1","volume":"62","author":"EK Thomsen","year":"2015","unstructured":"Thomsen, E. K. et al. Efficacy, safety, and pharmacokinetics of co-administered diethylcarbamazine, albendazole, and ivermectin for the treatment of bancroftian Filariasis. Clin. Infect. Dis. 62, 1\u20138 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"7826_CR6","doi-asserted-by":"publisher","first-page":"e0005163","DOI":"10.1371\/journal.pntd.0005163","volume":"11","author":"PU Fischer","year":"2017","unstructured":"Fischer, P. U., King, C. L., Jacobson, J. A. & Weil, G. J. Potential value of triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) to accelerate elimination of lymphatic filariasis and onchocerciasis in Africa. PLoS Negl. Trop. Dis. 11, e0005163 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"7826_CR7","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1056\/NEJMoa1705026","volume":"377","author":"J Kamgno","year":"2017","unstructured":"Kamgno, J. et al. A test-and-not-treat strategy for onchocerciasis in loa loa-endemic areas. N. Engl. J. Med. 377, 2044\u20132052 (2017).","journal-title":"N. Engl. J. Med."},{"key":"7826_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13071-014-0608-1","volume":"8","author":"S Wanji","year":"2015","unstructured":"Wanji, S. et al. Relationship between oral declaration on adherence to ivermectin treatment and parasitological indicators of onchocerciasis in an area of persistent transmission despite a decade of mass drug administration in Cameroon. Parasit. Vectors 8, 1\u201316 (2015).","journal-title":"Parasit. Vectors"},{"key":"7826_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0004905","volume":"10","author":"L Senyonjo","year":"2016","unstructured":"Senyonjo, L. et al. Factors associated with Ivermectin non-compliance and its potential role in sustaining Onchocerca volvulus transmission in the west region of cameroon. PLoS Negl. Trop. Dis. 10, 1\u201316 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"7826_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00430-007-0062-1","volume":"197","author":"A Hoerauf","year":"2008","unstructured":"Hoerauf, A. et al. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med. Microbiol. Immunol. 197, 295\u2013311 (2008).","journal-title":"Med. Microbiol. Immunol."},{"key":"7826_CR11","doi-asserted-by":"crossref","unstructured":"Turner, J. D. et al. Macrofilaricidal activity after doxycycline only treatment of Onchocerca volvulus in an area of Loa loa co-endemicity: a randomized controlled trial. PLoS Negl. Trop. Dis. 4, e660 (2010).","DOI":"10.1371\/journal.pntd.0000660"},{"key":"7826_CR12","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/S0140-6736(05)66591-9","volume":"365","author":"MJ Taylor","year":"2005","unstructured":"Taylor, M. J. et al. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet 365, 2116\u20132121 (2005).","journal-title":"Lancet"},{"key":"7826_CR13","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/cid\/ciu1152","volume":"60","author":"M Walker","year":"2015","unstructured":"Walker, M. et al. Therapeutic efficacy and macrofilaricidal activity of doxycycline for the treatment of river blindness. Clin. Infect. Dis. 60, 1199\u20131207 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"7826_CR14","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1111\/j.1365-3156.2007.01949.x","volume":"12","author":"AY Debrah","year":"2007","unstructured":"Debrah, A. Y. et al. Macrofilaricidal effect of 4\u2003weeks of treatment with doxycycline on Wuchereria bancrofti. Trop. Med. Int. Health 12, 1433\u20131441 (2007).","journal-title":"Trop. Med. Int. Health"},{"key":"7826_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/201617","volume":"2011","author":"AY Debrah","year":"2011","unstructured":"Debrah, A. Y. et al. Macrofilaricidal activity in Wuchereria bancrofti after 2 weeks treatment with a combination of rifampicin plus doxycycline. J. Parasitol. Res. 2011, 1\u20139 (2011).","journal-title":"J. Parasitol. Res."},{"key":"7826_CR16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/cid\/civ363","volume":"61","author":"AY Debrah","year":"2015","unstructured":"Debrah, A. Y. et al. Doxycycline leads to sterility and enhanced killing of female Onchocerca volvulus worms in an area with persistent microfilaridermia after repeated ivermectin treatment: a randomized, placebo-controlled, double-blind trial. Clin. Infect. Dis. 61, 517\u2013526 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"7826_CR17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1087057113511270","volume":"19","author":"KL Johnston","year":"2014","unstructured":"Johnston, K. L., Ford, L. & Taylor, M. J. M. Overcoming the challenges of drug discovery for neglected tropical diseases: the A\u00b7 WOL experience. J. Biomol. Screen. 19, 335\u2013343 (2014).","journal-title":"J. Biomol. Screen."},{"key":"7826_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1177\/1087057114551518","volume":"20","author":"RH Clare","year":"2014","unstructured":"Clare, R. H. et al. Development and validation of a high-throughput anti-wolbachia whole-cell screen: a route to macrofilaricidal drugs against onchocerciasis and lymphatic filariasis. J. Biomol. Screen. 20, 64\u201369 (2014).","journal-title":"J. Biomol. Screen."},{"key":"7826_CR19","first-page":"1","volume":"36","author":"KL Johnston","year":"2017","unstructured":"Johnston, K. L. et al. Identification and prioritization of novel anti-Wolbachia chemotypes from screening a 10,000-compound diversity library. Sci. Adv. 36, 1\u201311 (2017).","journal-title":"Sci. Adv."},{"key":"7826_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ijpddr.2014.09.001","volume":"4","author":"KL Johnston","year":"2014","unstructured":"Johnston, K. L. et al. Repurposing of approved drugs from the human pharmacopoeia to target Wolbachia endosymbionts of onchocerciasis and lymphatic filariasis. Int. J. Parasitol. Drugs Drug Resist. 4, 278\u2013286 (2014).","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"7826_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1021\/cc0000388","volume":"3","author":"TI Oprea","year":"2001","unstructured":"Oprea, T. I. & Gottfries, J. Chemography: the art of navigating in chemical space. J. Comb. Chem. 3, 157\u2013166 (2001).","journal-title":"J. Comb. Chem."},{"key":"7826_CR22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1359-6446(97)01083-0","volume":"2","author":"GM Rishton","year":"1997","unstructured":"Rishton, G. M. Reactive compounds and in vitro false positives in HTS. Drug Discov. Today 2, 382\u2013384 (1997).","journal-title":"Drug Discov. Today"},{"key":"7826_CR23","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1021\/ci990423o","volume":"39","author":"M Hann","year":"1999","unstructured":"Hann, M. et al. Strategic pooling of compounds for high-throughput screening. J. Chem. Inf. Comput. Sci. 39, 897\u2013902 (1999).","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"7826_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1023\/A:1008130001697","volume":"14","author":"TI Oprea","year":"2000","unstructured":"Oprea, T. I. Property distribution of drug-related chemical databases. J. Comput. Aided Mol. Des. 14, 251\u2013264 (2000).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"7826_CR25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/med.10041","volume":"23","author":"I Muegge","year":"2003","unstructured":"Muegge, I. Selection criteria for drug-like compounds. Med. Res. Rev. 23, 302\u2013321 (2003).","journal-title":"Med. Res. Rev."},{"key":"7826_CR26","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1021\/jm901137j","volume":"53","author":"JB Baell","year":"2010","unstructured":"Baell, J. B. & Holloway, G. A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53, 2719\u20132740 (2010).","journal-title":"J. Med. Chem."},{"key":"7826_CR27","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1021\/ci100050t","volume":"50","author":"D Rogers","year":"2010","unstructured":"Rogers, D. & Hahn, M. Extended-connectivity fingerprints. J. Chem. Inf. Model. 50, 742\u2013754 (2010).","journal-title":"J. Chem. Inf. Model."},{"key":"7826_CR28","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1021\/jm201388p","volume":"55","author":"Aacute Tarcsay","year":"2012","unstructured":"Tarcsay, \u00c1., Ny\u00edri, K. & Keser\u0171, G. M. Impact of lipophilic efficiency on compound quality. J. Med. Chem. 55, 1252\u20131260 (2012).","journal-title":"J. Med. Chem."},{"key":"7826_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00322-5","volume":"7","author":"G Aljayyoussi","year":"2017","unstructured":"Aljayyoussi, G. et al. Short-course, high-dose rifampicin achieves Wolbachia depletion predictive of curative outcomes in preclinical models of lymphatic filariasis and onchocerciasis. Sci. Rep. 7, 210 (2017).","journal-title":"Sci. Rep."},{"key":"7826_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/srep23458","volume":"6","author":"R Sharma","year":"2016","unstructured":"Sharma, R. et al. Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis. Sci. Rep. 6, 23458 (2016).","journal-title":"Sci. Rep."},{"key":"7826_CR31","doi-asserted-by":"crossref","unstructured":"Sanz, L. M. et al. P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action. PLoS ONE 7, e30949 (2012).","DOI":"10.1371\/journal.pone.0030949"},{"key":"7826_CR32","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1021\/jm000139k","volume":"43","author":"GR Brown","year":"2000","unstructured":"Brown, G. R. et al. A novel series of 4-piperidinopyridine and 4-piperidinopyrimidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase. J. Med. Chem. 43, 4964\u20134972 (2000).","journal-title":"J. Med. Chem."},{"key":"7826_CR33","doi-asserted-by":"crossref","unstructured":"Geoghegan, V. et al. Perturbed cholesterol and vesicular trafficking associated with dengue blocking in Wolbachia-infected Aedes aegypti cells. Nat. Commun. 8, 526 (2017).","DOI":"10.1038\/s41467-017-00610-8"},{"key":"7826_CR34","doi-asserted-by":"publisher","first-page":"22364","DOI":"10.1074\/jbc.M901528200","volume":"284","author":"JD Turner","year":"2009","unstructured":"Turner, J. D. et al. Wolbachia lipoprotein stimulates innate and adaptive immunity through toll-like receptors 2 and 6 to induce disease manifestations of filariasis. J. Biol. Chem. 284, 22364\u201322378 (2009).","journal-title":"J. Biol. Chem."},{"key":"7826_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/laban0510-143","volume":"39","author":"KG Griffiths","year":"2010","unstructured":"Griffiths, K. G., Alworth, L. C., Harvey, S. B. & Michalski, M. L. Using an intravenous catheter to carry out abdominal lavage in the gerbil. Lab Anim. 39, 143\u2013148 (2010).","journal-title":"Lab Anim."},{"key":"7826_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.molbiopara.2004.01.006","volume":"135","author":"HF McGarry","year":"2004","unstructured":"McGarry, H. F., Egerton, G. L. & Taylor, M. J. Population dynamics of Wolbachia bacterial endosymbionts in Brugia malayi. Mol. Biochem. Parasitol. 135, 57\u201367 (2004).","journal-title":"Mol. Biochem. Parasitol."},{"key":"7826_CR37","doi-asserted-by":"publisher","first-page":"6060","DOI":"10.1021\/jm500462x","volume":"57","author":"GS Basarab","year":"2014","unstructured":"Basarab, G. S. et al. Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099). J. Med. Chem. 57, 6060\u20136082 (2014).","journal-title":"J. Med. Chem."},{"key":"7826_CR38","doi-asserted-by":"publisher","first-page":"9457","DOI":"10.1021\/acs.jmedchem.6b01127","volume":"59","author":"K Doyle","year":"2016","unstructured":"Doyle, K. et al. Discovery of second generation reversible covalent dpp1 inhibitors leading to an oxazepane amidoacetonitrile based clinical candidate (AZD7986). J. Med. Chem. 59, 9457\u20139472 (2016).","journal-title":"J. Med. Chem."},{"key":"7826_CR39","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1021\/ci500588j","volume":"55","author":"T Sander","year":"2015","unstructured":"Sander, T., Freyss, J., von Korff, M. & Rufener, C. DataWarrior: an open-source program for chemistry aware data visualization and analysis. J. Chem. Inf. Model. 55, 460\u2013473 (2015).","journal-title":"J. Chem. Inf. Model."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-07826-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-07826-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-07826-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T13:29:54Z","timestamp":1671197394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-07826-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,2]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["7826"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-07826-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,2]]},"assertion":[{"value":"26 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.B., P.H., U.B., D.P., H.P. and M.W. are employees and therefore shareholders of AstraZeneca, however, they have no financial or intellectual property rights to the structures presented in this manuscript which were transferred to the LSTM, a charitable organisation. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}